GPX4 and lung carcinoma: Importantly, GPX4 was positively correlated with resistance of lung cancer cells to L-685458, lapatinib, paposilli, and topotecan, suggesting that targeting System Xc−/GSH/GPX4 axis could overcome drug resistance (Zhang et al., 2020; Ni J. et al., 2021).